Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils

Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes

(2022) Amer M. Zeidan et al.   ANNALS OF HEMATOLOGY

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy

(2022) Huanpeng Chen et al.   Journal for ImmunoTherapy of Cancer

Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex

(2022) Dieke J van Rees et al.   Journal for ImmunoTherapy of Cancer

ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer

(2022) Rodney Cheng-En Hsieh et al.   Science Immunology

Phase 1 Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2021) Stephen M Ansell et al.   CLINICAL CANCER RESEARCH

RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopenia

(2021) Bryan Oronsky et al.   Expert Opinion on Drug Metabolism & Toxicology

Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer

(2021) Fangqiu Fu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC

(2021) Kaixin Du et al.   MOLECULAR THERAPY

Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells

(2021) Kate J. Dixon et al.   Cancers

In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit

(2021) Yusuke Tomita et al.   Translational Lung Cancer Research

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis

(2021) Chang Cui et al.   CELL

The ever‐increasing importance of cancer as a leading cause of premature death worldwide

(2021) Freddie Bray et al.   CANCER

Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody

(2021) Haiqing Ni et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions

(2021) Niklas Baumann et al.   CANCER SCIENCE

AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

(2021) David Sallman et al.   Clinical Lymphoma Myeloma & Leukemia

Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development

(2021) Bryan Oronsky et al.   JOURNAL OF MEDICINAL CHEMISTRY

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance

(2021) Rosalynd Upton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation

(2021) Zhiqiang Li et al.   Translational Oncology

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells

(2021) Paula Martínez-Sanz et al.   Cancers

The selection of variable regions affects effector mechanisms of IgA antibodies against CD20

(2021) Mitchell Evers et al.   Blood Advances

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)

(2021) Guillermo Garcia-Manero et al.   BLOOD

Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin's Lymphoma: Initial Clinical Results

(2021) Amitkumar Mehta et al.   BLOOD

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

(2021) Steven M. Horwitz et al.   BLOOD

Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

(2021) Paolo Strati et al.   BLOOD

Discovery and Preclinical Characterization of CC-95251, an Anti-SIRPα Antibody That Enhances Macrophage-Mediated Phagocytosis of Non-Hodgkin Lymphoma (NHL) Cells When Combined with Rituximab

(2021) Henry Chan et al.   BLOOD

CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

(2021) Krish Patel et al.   BLOOD

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

(2021) Nehal J Lakhani et al.   LANCET ONCOLOGY

Versatile neutrophil functions in cancer

(2021) Marie Siwicki et al.   SEMINARS IN IMMUNOLOGY

The dual role of neutrophils in cancer

(2021) Merav E. Shaul et al.   SEMINARS IN IMMUNOLOGY

Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study

(2021) Christiane Querfeld et al.   Lancet Haematology

498 Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01

(2021) Keun-Wook Lee et al.   Journal for ImmunoTherapy of Cancer

Role of Tumor-Associated Neutrophils in the Molecular Carcinogenesis of the Lung

(2021) Elisabeth Taucher et al.   Cancers

Galectin-9 Triggers Neutrophil-Mediated Anticancer Immunity

(2021) Natasha Ustyanovska Avtenyuk et al.   Biomedicines

Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20-opsonized B cells to neutrophil killing

(2021) Dieke J. van Rees et al.   Blood Advances

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

(2020) David A Sallman et al.   BLOOD

Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States

(2020) Amer M. Zeidan et al.   BLOOD

Antibody‐mediated complement activation in pathology and protection

(2020) Benjamin S. Goldberg et al.   IMMUNOLOGY AND CELL BIOLOGY

A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.

(2020) George A. Fisher et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies

(2020) Mark P. Chao et al.   Frontiers in Oncology

Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma

(2020) Cristina Perez et al.   BLOOD

Immune checkpoint signaling and cancer immunotherapy

(2020) Xing He et al.   CELL RESEARCH

CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

(2020) Álvaro Teijeira et al.   IMMUNITY

Two-Faced Roles of Tumor-Associated Neutrophils in Cancer Development and Progression

(2020) Naofumi Mukaida et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.

(2020) David Andrew Sallman et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a first-in-human phase I study of SRF231, a fully human, high-affinity anti-CD47 antibody.

(2020) Amita Patnaik et al.   JOURNAL OF CLINICAL ONCOLOGY

Neutrophils at the crossroads of innate and adaptive immunity

(2020) Carlos Rosales   JOURNAL OF LEUKOCYTE BIOLOGY

A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology

(2020) Teresa L. Burgess et al.   PLoS One

CD47 Ligation Repositions the Inhibitory Receptor SIRPA to Suppress Integrin Activation and Phagocytosis

(2020) Meghan A. Morrissey et al.   IMMUNITY

DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25

(2020) Linbin Yang et al.   NATURE

Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance

(2020) Vanessa Gauttier et al.   JOURNAL OF CLINICAL INVESTIGATION

SIRPα on Mouse B1 Cells Restricts Lymphoid Tissue Migration and Natural Antibody Production

(2020) Katka Franke et al.   Frontiers in Immunology

Innate immune checkpoints for cancer immunotherapy: expanding the scope of non T cell targets

(2020) Luis F. Campesato et al.   Annals of Translational Medicine

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

(2020) Sreya Bagchi et al.   Annual Review of Pathology-Mechanisms of Disease

EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles

(2020) Elias da Silva Santos et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity

(2020) Tracy C. Kuo et al.   Journal of Hematology & Oncology

Kindlin3-dependent CD11b/CD18-integrin activation is required for potentiation of neutrophil cytotoxicity by CD47-SIRPα checkpoint disruption

(2020) Panagiota Bouti et al.   Cancer Immunology Research

Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN activation

(2019) Josée Golay et al.   BLOOD

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy

(2019) Meike E. W. Logtenberg et al.   NATURE MEDICINE

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

(2019) Branimir I. Sikic et al.   JOURNAL OF CLINICAL ONCOLOGY

Neutrophil Cell Shape Change: Mechanism and Signalling during Cell Spreading and Phagocytosis

(2019) Rhiannon Roberts et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Role of Tumor-Associated Neutrophils in Colorectal Cancer

(2019) Rei Mizuno et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

(2019) Y Fradet et al.   ANNALS OF ONCOLOGY

Identification of Glutaminyl Cyclase isoenzyme isoQC as a regulator of SIRPα-CD47 axis

(2019) Zhiqiang Wu et al.   CELL RESEARCH

RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages

(2019) Pedro Cabrales   Translational Oncology

The effects of monoclonal anti‐CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia

(2019) C.K. Brierley et al.   TRANSFUSION

Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG

(2019) Arianne M. Brandsma et al.   Frontiers in Immunology

REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer

(2019) Bryan Oronsky et al.   Future Oncology

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

(2019) Pau Abrisqueta et al.   BLOOD

IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47–SIRPα Checkpoint Inhibition

(2019) Louise W. Treffers et al.   Cancer Immunology Research

Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy

(2019) Maria Teresa Masucci et al.   Frontiers in Oncology

Monoclonal antibody-mediated killing of tumour cells by neutrophils

(2018) Niels Heemskerk et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

The promise and challenges of immune agonist antibody development in cancer

(2018) Patrick A. Mayes et al.   NATURE REVIEWS DRUG DISCOVERY

SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-κB-CD47 axis

(2018) Fei Liu et al.   ONCOGENE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Bispecific antibodies: design, therapy, perspectives

(2018) Sergey Sedykh et al.   Drug Design Development and Therapy

Tumor-derived granzyme B-expressing neutrophils acquire antitumor potential after lipid A treatment

(2018) Amandine Martin et al.   Oncotarget

Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis

(2018) Hanke L. Matlung et al.   Cell Reports

Recent advances on the crosstalk between neutrophils and B or T lymphocytes

(2018) Sara Costa et al.   IMMUNOLOGY

ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile

(2018) Steven E. Kauder et al.   PLoS One

Monoclonal antibodies in cancer immunotherapy

(2018) Ilgin Kimiz-Gebologlu et al.   MOLECULAR BIOLOGY REPORTS

Immune Effector Functions of Human IgG2 Antibodies against EGFR

(2018) Thies Rösner et al.   MOLECULAR CANCER THERAPEUTICS

Integrin activation by talin, kindlin and mechanical forces

(2018) Zhiqi Sun et al.   NATURE CELL BIOLOGY

Myeloid immune-checkpoint inhibition enters the clinical stage

(2018) Timo K. van den Berg et al.   Nature Reviews Clinical Oncology

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer

(2017) Hanke L. Matlung et al.   IMMUNOLOGICAL REVIEWS

Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity

(2017) Nan Guo Ring et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Blocking the CD47-SIRPα axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells

(2017) Feng Li et al.   OncoImmunology

TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets

(2017) Gloria H. Y. Lin et al.   PLoS One

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

(2016) Penka S. Petrova et al.   CLINICAL CANCER RESEARCH

Neutrophils in cancer

(2016) Louise W. Treffers et al.   IMMUNOLOGICAL REVIEWS

Granulopoiesis and granules of human neutrophils

(2016) Jack B. Cowland et al.   IMMUNOLOGICAL REVIEWS

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer

(2016) Kipp Weiskopf et al.   JOURNAL OF CLINICAL INVESTIGATION

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells

(2016) D Sharma Das et al.   LEUKEMIA

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

(2016) Jonathan T. Sockolosky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis

(2016) Michel W. P. Tsang-A-Sjoe et al.   RHEUMATOLOGY

Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis

(2016) Silvia Guglietta et al.   Nature Communications

Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2

(2015) Eric F. Zhu et al.   CANCER CELL

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect

(2015) David J. DiLillo et al.   CELL

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study

(2015) Tony Reid et al.   LANCET ONCOLOGY

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

(2015) Alexander M M Eggermont et al.   LANCET ONCOLOGY

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulation of Phagocyte Migration by Signal Regulatory Protein-Alpha Signaling

(2015) Julian Alvarez-Zarate et al.   PLoS One

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

(2015) Kim C. Ohaegbulam et al.   TRENDS IN MOLECULAR MEDICINE

CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models

(2015) Ji-Feng Xu et al.   Oncotarget

Neutrophils in Cancer: Two Sides of the Same Coin

(2015) Eileen Uribe-Querol et al.   Journal of Immunology Research

Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all?

(2015) Sietse Q. Nagelkerke et al.   Frontiers in Immunology

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential

(2015) Jie Liu et al.   PLoS One

Complement in monoclonal antibody therapy of cancer

(2014) Laura M. Rogers et al.   IMMUNOLOGIC RESEARCH

Signal-regulatory proteinαfrom the NOD mouse binds human CD47 with an exceptionally high affinity - implications for engraftment of human cells

(2014) Lai Shan Kwong et al.   IMMUNOLOGY

Polymorphisms in the Human Inhibitory Signal-regulatory Protein α Do Not Affect Binding to Its Ligand CD47

(2014) Deborah Hatherley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

(2014) Nuray Gül et al.   JOURNAL OF CLINICAL INVESTIGATION

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

(2014) Arnoud J. Templeton et al.   JNCI-Journal of the National Cancer Institute

IgG Subclasses and Allotypes: From Structure to Effector Functions

(2014) Gestur Vidarsson et al.   Frontiers in Immunology

The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target

(2013) A. Neil Barclay et al.   Annual Review of Immunology

Polymorphic Sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment

(2013) T. Yamauchi et al.   BLOOD

Neutrophils mediate antibody-induced antitumor effects in mice

(2013) M. Albanesi et al.   BLOOD

NETosis: how vital is it?

(2013) B. G. Yipp et al.   BLOOD

The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer

(2013) Graeme J.K. Guthrie et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

SHPS-1 and a synthetic peptide representing its ITIM inhibit the MyD88, but not TRIF, pathway of TLR signaling through activation of SHP and PI3K in THP-1 cells

(2013) Eun-Ju Kim et al.   INFLAMMATION RESEARCH

Neutrophil cell surface receptors and their intracellular signal transduction pathways

(2013) Krisztina Futosi et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

An Extracellular Matrix-Based Mechanism of Rapid Neutrophil Extracellular Trap Formation in Response to Candida albicans

(2013) A. S. Byrd et al.   JOURNAL OF IMMUNOLOGY

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

(2013) D. Tseng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Engineered SIRP  Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies

(2013) K. Weiskopf et al.   SCIENCE

Cancer Immunotherapy

(2013) J. Couzin-Frankel   SCIENCE

A proposed role for neutrophil extracellular traps in cancer immunoediting

(2013) Sivan Berger-Achituv et al.   Frontiers in Immunology

Neutrophil Function: From Mechanisms to Disease

(2012) Borko Amulic et al.   Annual Review of Immunology

Is targeting of CD47-SIRP  enough for treating hematopoietic malignancy?

(2012) X. W. Zhao et al.   BLOOD

Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells

(2012) Marielle A. Otten et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy

(2012) L. Bologna et al.   JOURNAL OF IMMUNOLOGY

Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo

(2012) Bryan G Yipp et al.   NATURE MEDICINE

On the mechanism of CD47 targeting in cancer

(2012) X. W. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Flipping the script on macrophages in leiomyosarcoma

(2012) Badreddin Edris et al.   OncoImmunology

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy

(2011) M. P. Chao et al.   BLOOD

Antibody-Dependent Cell Cytotoxicity Synapses Form in Mice during Tumor-Specific Antibody Immunotherapy

(2011) P. Hubert et al.   CANCER RESEARCH

Immunoglobulin A

(2011) Jantine E. Bakema et al.   mAbs

The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity

(2011) J E Bakema et al.   Mucosal Immunology

CD47-signal regulatory protein-  (SIRP ) interactions form a barrier for antibody-mediated tumor cell destruction

(2011) X. W. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days

(2010) J. Pillay et al.   BLOOD

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

Neutrophils, from Marrow to Microbes

(2010) Niels Borregaard   IMMUNITY

A Novel Mechanism of Rapid Nuclear Neutrophil Extracellular Trap Formation in Response to Staphylococcus aureus

(2010) F. H. Pilsczek et al.   JOURNAL OF IMMUNOLOGY

Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models

(2010) William M. Siders et al.   LEUKEMIA & LYMPHOMA

Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN

(2009) Zvi G. Fridlender et al.   CANCER CELL

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

Immunoglobulin A: FcαRI Interactions Induce Neutrophil Migration Through Release of Leukotriene B4

(2009) Lydia van der Steen et al.   GASTROENTEROLOGY

SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels

(2009) Ulrike Lorenz   IMMUNOLOGICAL REVIEWS

Specificity and affinity of human Fc  receptors and their polymorphic variants for human IgG subclasses

(2008) P. Bruhns et al.   BLOOD

Dynamics of Neutrophil Migration in Lymph Nodes during Infection

(2008) Tatyana Chtanova et al.   IMMUNITY

Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells

(2008) Richard K. Tsai et al.   JOURNAL OF CELL BIOLOGY

Paired Receptor Specificity Explained by Structures of Signal Regulatory Proteins Alone and Complexed with CD47

(2008) Deborah Hatherley et al.   MOLECULAR CELL

Innate immune ‘self’ recognition: a role for CD47–SIRPα interactions in hematopoietic stem cell transplantation

(2008) Timo K. van den Berg et al.   TRENDS IN IMMUNOLOGY

Role of different protein tyrosine kinases in fMLP-induced neutrophil transmigration

(2007) Ke Zen et al.   IMMUNOBIOLOGY